Rubicrono® extended release tablets EFG

THERAPEUTIC INDICATION

Rubicrono® extended release tablets EFG

Rubicrono® extended release tablets EFG is ndicated as part of a comprehensive treatment program for Attention Deficit Hyperactivity Disorder (ADHD) in children from 6 years of age when other measures, by themselves, have proven insufficient. Treatment should be under the supervision of a specialist in behavioral disorders in children. Diagnosis should be made according to current DSM criteria or ICD guidelines and should be based on a complete history and evaluation of the patient. The diagnosis cannot be made solely on the presence of one or more symptoms.
The specific etiology of this syndrome is unknown, and there is no single diagnostic test. For an adequate diagnosis it is necessary to resort to clinical and specialized psychology, and to social and educational resources.

A comprehensive treatment program generally includes psychological, educational, and social measures as well as pharmacotherapy and is intended to stabilize children with a behavioral syndrome characterized by symptoms that may include a chronic history of difficulty paying attention, being easily distracted, emotional lability, impulsiveness, moderate to severe hyperactivity, minor neurological signs, and abnormal EEG. Learning ability may or may not be impaired.

Treatment with Rubicrono^® is not indicated for all children with ADHD and the decision to use the drug must be based on a very complete evaluation of the severity and chronicity of the child’s symptoms in relation to her age.

An appropriate educational placement is essential, and psychosocial intervention is often necessary. When other measures alone have proven insufficient, the decision to prescribe a stimulant should be based on a rigorous assessment of the severity of the child’s symptoms. The use of methylphenidate should always be done in this way according to the authorized indication and according to the prescription and diagnostic guidelines.